陽普醫療(300030.SZ):新型冠狀病毒核酸檢測試劑盒(PCR-熒光探針法)獲得CE認證
格隆匯3月30日丨陽普醫療(300030.SZ)公佈,公司今日獲悉,公司研發的新型冠狀病毒(SARS-CoV-2)核酸檢測試劑盒(PCR-熒光探針法)獲得歐盟CE認證。該核酸檢測產品為新冠肺炎的疑似患者、無症狀患者、密切接觸者提供PCR實驗室檢測手段,為疾控部門和醫療機構提供診斷參考依據,在全球範圍內助力新型冠狀病毒感染的疫情防控工作。
取得CE認證,表明該系列產品符合歐盟相關要求,已經具備歐盟市場的准入條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.